Paradigm Biopharmaceuticals Ltd. has released a press release.
Paradigm receives clarity on US regulatory pathway
Filed with ASX ·
6ix hasn’t read this filing yet.
Paradigm Biopharmaceuticals Ltd. on 6ix
In the deck
Earlier from Paradigm Biopharmaceuticals
- Paradigm Latest Corporate Presentation
- Voluntary Suspension
- All 10 participants in US FDA EAP have commenced treatment
- Paradigm reports Positive Pre-IND meeting with US FDA
- Paradigm - first patient dosed in USA under FDA approved EAP
Later from Paradigm Biopharmaceuticals
- Paradigm Reports Very Encouraging Real World Data
- Paradigm completes $35m raising
- Reinstatement to Official Quotation
- EAP treatment completed and Orphan Status achieved for MPS-I
- Block trade to institutional investors
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals